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Poster Session I S301nutrition. Red cell requirement was\ 4 units in 9 children and . 4
units in 11 children. Platelet support was required\5 in 5 children
and. 5 in 15 children. Two of the eighteen children did not engraft
and 4 children had graft versus host disease and 1 child died on day 10
due to acute cardiomyopathy. Two children had mild sinusoidal ob-
struction syndrome. Group two had 9 class I, 3 class II and 8 class III
patients between age groups 1 to 13 years. Mucositis was grade two
and above in 5 children and they needed partial parenteral nutrition.
Less than 4 units of red cells were required in 15 children and . 4
units in 5 children. Platelet support was required on less than occa-
sions in 10 children and . 5 in 10 children. All of the eighteen chil-
dren engrafted and 2 children had graft versus host disease. There
was no mortality and two children had early graft rejection before
day 100. No child had sinusoidal obstruction syndrome.
We conclude that this treosulphan based regimen is well tolerated
and results in durable engraftment even in Class III thalassaemia ma-
jor children with no major toxicity or mortality.
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PULMONARY ARTERYOPATHY AND PULMONARY HYPERTENSION FOL-
LOWING TANDEMAUTOLOGOUS TRANSPLANTS IN PEDIATRIC PATIENTS
WITH CNS TUMORS
Schechter, T.1, Leucht, S.1, Bouffet, E.1, Cutz, E.2,Gassas, A.1,Huang,A.1,
Bartels, U.1, Humpl, T.3, Doyle, J.1 1The Hospital for Sick Children,
Toronto, ON, Canada; 2The Hospital for Sick Children, Toronto, ON,
Canada; 3The Hospital for Sick Children, Toronto, ON, Canada
Introduction: Young children with central nervous system (CNS)
tumors are frequently being treated with tandem cycles of high
dose chemotherapy followed by autologous stem-cell transplants in
an attempt to avoid cranial irradiation. The most common combina-
tions of chemotherapy used is carboplatinum and thiotepa. Though,
multiple side effects were documented, pulmonary arteriopathy
leading to pulmonary hypertension (PH) was not previously docu-
mented in patients treated for primary CNS disease. We herein re-
port PH as a complication post autologous transplantation using
carboplatinum and thiotepa as conditioning therapy.
Methods: A retrospective evaluation of all pediatric patients diag-
nosed with primary CNS tumors between 2001-2010 who were
scheduled to be treated with 3 cycles of high dose chemotherapy
with carboplatinum (17mg/kd/day for 2 days) and thiotepa (10mg/
kg/day for 2 days) followed by autologous stem-cell transplants
was conducted. The primary objective was to evaluate the incidence
of PH in this population and patients’ outcome following the devel-
opment of PH.
Results: 14 patients were scheduled to received 3 cycles of autolo-
gous transplantation. The median age was 28 months (range
3-41months). Patients’ diagnoses were: atypical teratoid rhabdoid
tumor – 8 patients, medulloblastoma- 4 patients and primitive neu-
roectodermal tumor- 2 patients. Three patients developed biopsy
confirmed pulmonary arteriopathy. The two patients that developed
echocardiographic evidence of PH after the third cycle of high dose
therapy succumbed to right heart failure, while one patient who’s PH
was detected after the second cycle didn’t receive the third cycle and
survived this complication. The overall survival (OS) of the 14 pa-
tients was 0.48 +/- 0.15 at a median of 14.32 months (range 4.99-
68.21 months). Death from progression was 0.43 +/- 0.16 and
non-relapsed mortality was 0.15 +/- 0.10. The 2 patients who died
from PH represented the only non-relapsed mortality in our cohort.
Conclusions: Pulmonary hypertension is a major complication fol-
lowing high dose chemotherapy and autologous transplantation with
a high likelihood of mortality despite PH directed therapy. Echocar-
diographic evaluation of the right ventricle and screening specifically
for PH should be included after each cycle of high dose chemother-
apy in pediatric CNS tumor population. Consideration for longer
interval between cycles should be done to allow proper follow-up be-
tween cycles.
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OUTCOMES OF HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR
INHERITED METABOLIC DISORDERS: A REPORT FROM ANZCHOG AND
ABMTRR
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tralia; 2Australasian Bone Marrow Transplant Recipient Registry, Syd-
ney, Australia; 3Royal Children’s Hospital, Melbourne, Australia;
4Children’s Hospital Westmead, Sydney, Australia; 5Starship Children’s
Hospital, Auckland, New Zealand; 6Royal Children’s Hospital, Brisbane,
Australia; 7Women and Children’s Hospital, Adelaide, Australia; 8Prin-
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We report a retrospective analysis of 53 haematopoietic stem cell
transplants for inherited metabolic disorders performed at Australia
and New Zealand Children’s Haematology Oncology Group
(ANZCHOG) transplant centres between 1992 and 2008. The
most common indications for transplant were Hurler syndrome
(47%), adrenoleukodystrophy (ALD) (28%) and metachromatic
leukodystrophy (17%). The median age of patients was 2 years
(0-15). 11 (32%) patients received marrow from matched siblings,
1 from an HLA-identical parent. The remaining 66% received
grafts from unrelated donors, with 22 (42%) using single UCB,
13 BM or PBSC (23%) and one double UCB transplant. 55% of pa-
tients received Busulphan and Cyclophosphamide as their condi-
tioning regimen, and 34% received Bu/Cy + Other (Melphalan or
Fludarabine). 54% had in-vivo T cell depletion using ATG or
Campath, and 15% had ex-vivo T cell depletion. Median time to
neutrophil and platelet engraftment was 16 and 35 days respec-
tively, with a cumulative incidence (CI) at day +42 of 94% and
73% respectively. There were 3 graft failures, all engrafted after
a second URD, and are alive at 10, 5 and 3 years post transplant.
The CI of aGVHD grade II-IV and III-IV at day +100 was 39%
and 14% respectively. 17% of patients had cGVHD at 1 year
post transplant. Transplant related mortality (TRM) was 12% at
day +100, and 19% at 1 year post transplant. Overall 5 year survival
(OS) was 78% for the cohort, with 73% for ALD and 83% for
Hurler syndrome. There were no late deaths reported for the co-
hort, with median follow up of 4 years. Neither age, year of trans-
plant, donor source, or HLA match impacted OS. In contrast, the
development of interstitial pneumonitis was the only significant var-
iable associated with an increase in TRM and decrease in OS. This
is keeping with previously reported literature for this patient co-
hort1. In summary, we report excellent OS in a large cohort of pa-
tients transplanted for a range of metabolic disorders.
1. Orchard PJ,Milla C, Braulin E et al. ‘‘Pre-transplant risk factors
affecting outcome in Hurler syndrome’’ Bone marrow transplant.
(2010) 45: 1239-1246.263
CHEMOTHERAPY-ONLY PREPARATIVE REGIMEN FOR ALTERNATIVE DO-
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WITH FANCONI ANEMIA
Mehta, P.A.1, Davies, S.M.1, Duncan, C.2, Guinan, E.2, Klein, E.4,
Edwards, S.1, Lehmann, L.2, Margolis, D.3, Williams, D.2, Boulad, F.4
1Cincinnati Children’s Hospital Medical Center, OH; 2Boston Children’s
Hospital, MA; 3Children’s Hospital of Wisconsin, WI; 4Memorial Sloan-
Kettering Hospital, NY
Background: A significant number of patients with Fanconi anemia
(FA) who survive hematopoietic stem cell transplantation (HSCT),
develop solid tumors. The relative contributions of total body irradi-
ation (TBI) and chronic graft vs. host disease (GvHD) to the devel-
opment of tumors are unknown. Our study aims to examine whether
non-TBI based preparative regimen improves alternative donor
HSCToutcome in FA.Here we report results of our interim analysis
after first 17 patients.
Methods: Seventeen patients were enrolled in this phase II multi-
center protocol between June 2009 and October 2011. See Table 1
for patient and donor characteristics. Preparative regimen in-
cluded: Busulfan 0.8-1.0 mg/Kg/dose Q 12H x 4 doses (D-7&-6),
Cyclophosphamide 10 mg/Kg/day, Fludarabine 35 mg/m2/day and
Rabbit ATG 2.5 mg/Kg/day x 4 days (D-5 to D-2).GvHD pro-
phylaxis was cyclosporine starting D-2. Filgrastim was used starting
D+1. Busulfan doses were adjusted to keep the steady state con-
centration low in most cases. All grafts were T-cell depleted using
the CliniMacs CD34 columns (Miltenyi). Cell doses of the grafts
were: 4.9 -42.7 x 106 CD34 cells/Kg and 2.24- 49.90 x 103 CD3
cells/Kg.
